Alabama-Clinical Trials Unit

阿拉巴马州临床试验单位

• 批准号: 8145929
• 负责人: Michael S. Saag
• 金额: $ 112.09万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-23 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8145929
• 关键词: AIDS Vaccines; AIDS clinical trial group; AIDS prevention; Acquired Immunodeficiency Syndrome; Address; Adolescent; Adult; African American; Alabama; Area; Basic Science; Caring; Childhood; Clinical; Clinical Management; Clinical Research; Clinical Trials; Clinical Trials Unit; Commit; Communities; Comorbidity; Epidemic; Failure; Funding; HIV; HIV Infections; HIV Vaccine Trials Network; HIV prevention trials network; HIV vaccine; Heart; Individual; Industry; Infant; Infection; Investigation; Mothers; National Institute of Allergy and Infectious Disease; Participant; Patients; Populations at Risk; Prevention; Prevention Research; Preventive Intervention; Research; Research Personnel; Resources; Site; Southeastern United States; Therapeutic; Toxic effect; United States; Universities; Vaccine Research; Vaccines; Vertical Disease Transmission; Virus; Vulnerable Populations; Woman; antiretroviral therapy; clinical research site; drug development; experience; microbicide; pediatric AIDS; response; success; vaccine evaluation

DESCRIPTION (provided by applicant): Despite the tremendous progress in the treatment and prevention of HIV infection in the United States there remain significant deficiencies in care and prevention. Antiretroviral therapy failure occurs, unexpected toxicities have emerged, long-term secondary complications have arisen, mother-to-child transmission still befalls mothers and infants in resource poor settings, and the rate of infection continues unabated. The Southeastern United States has the fastest rising number of new HIV infections in the U.S., particularly among African American women. This places Alabama and the University of Alabama Birmingham (UAB) in the heart of this growing epidemic that disproportionately afflicts the most vulnerable populations. This is confounded by the fact that an estimated 50% of infected individuals in this region are unaware they are carrying the virus. The UAB Center for AIDS Research (CFAR) has been at the forefront of HIV prevention and therapeutic investigation for over 18 years. The UAB CFAR is committed to providing the most modern, up to date, therapeutic and prevention interventions to patients and at-risk populations in our State. In response to the NIAID's call for site applications to perform clinical studies that address the emerging issues in HIV treatment and prevention, the UAB CFAR has formed the Alabama-Clinical Trials Unit (A-CTU): A partnership of UAB investigators dedicated to the conduct of high-impact HIV-related studies in a resource poor region of the United States. The A-CTU is comprised of an efficient Central Administration and four Clinical Research Sites (CRS): Alabama Therapeutics-CRS (AT-CRS), The Alabama Vaccine-CRS (AV-CRS), The Alabama Pediatric, Adolescent & Maternal-CRS (APAM-CRS), and The Alabama Microbicide-CRS (AM-CRS). The A-CTU draws on tremendous experience and success in NIAID-sponsored research trials groups, including over 13 years of involvement in the Adult and Pediatric AIDS Clinical Trials Group (AACTG; PACTG), 12 years experience in the HIV Prevention Trials Network (HPTN), and 11 years of continuous involvement as a federally funded HIV vaccine trials site under the AIDS Vaccine Evaluation Group and the HIV Vaccine Trials Network. Owing to this wealth of experience, we are submitting this single coordinated CTU application in response to 5 of the 6 High-Profile Targeted Areas of Investigation: Vaccine research, translational and drug development research, optimization of clinical management research (including comorbidities), microbicide research, and prevention of mother-to-child transmission research. Addressing these Priority Areas will be accomplished through utilization of the A-CTU's genuine partnership with the patient/participant community, its experience in NIAID and industry-funded clinical trials, and through collaborative research among clinical and basic science investigators within the UAB CFAR. ADMINISTRATIVE COMPONENT:

描述（由申请人提供）：尽管美国在治疗和预防艾滋病毒感染方面取得了巨大进展，但在护理和预防方面仍然存在重大缺陷。抗逆转录病毒治疗失败，出现意想不到的毒性，出现长期继发并发症，母婴传播仍然发生在资源匮乏的环境中的母亲和婴儿身上，感染率有增无减。美国东南部地区的新艾滋病毒感染人数上升最快，尤其是非裔美国女性。这使得阿拉巴马州和阿拉巴马大学伯明翰分校 (UAB) 处于这一日益严重的流行病的中心，这种流行病尤其困扰着最脆弱的人群。令人困惑的是，该地区估计有 50% 的感染者不知道自己携带病毒。 UAB 艾滋病研究中心 (CFAR) 18 年来一直处于艾滋病毒预防和治疗研究的最前沿。 UAB CFAR 致力于为我们州的患者和高危人群提供最现代、最新的治疗和预防干预措施。为了响应 NIAID 要求现场申请开展临床研究以解决 HIV 治疗和预防中新出现问题的要求，UAB CFAR 成立了阿拉巴马州临床试验单位 (A-CTU)：UAB 研究人员的合作伙伴关系，致力于在资源匮乏的地区开展高影响力的 HIV 相关研究。 美国。 A-CTU 由高效的中央管理部门和四个临床研究中心组成 站点 (CRS)：阿拉巴马州治疗学-CRS (AT-CRS)、阿拉巴马州疫苗-CRS (AV-CRS)、阿拉巴马州儿科、青少年和孕产妇-CRS (APAM-CRS) 和阿拉巴马州杀菌剂-CRS (AM-CRS)。 A-CTU 借鉴了 NIAID 资助的研究试验小组的巨大经验和成功，包括超过 13 年参与成人和儿童艾滋病临床试验小组 (AACTG; PACTG)、12 年 HIV 预防试验网络 (HPTN) 经验以及 11 年作为联邦资助的艾滋病疫苗评估小组和 HIV 疫苗试验中心的持续参与 试炼网．凭借丰富的经验，我们提交这份单一的协调 CTU 申请，以响应 6 个备受瞩目的目标研究领域中的 5 个：疫苗研究、转化和药物开发研究、临床管理研究的优化（包括合并症）、杀菌剂研究和预防母婴传播研究。解决这些优先领域的问题将通过利用 A-CTU 与患者/参与者社区的真正合作伙伴关系、其在 NIAID 和行业资助的临床试验方面的经验，以及通过 UAB CFAR 内临床和基础科学研究人员之间的合作研究来完成。 行政部分：